Androgen receptor cofactors in prostate cancer: Potential therapeutic targets of castration-resistant prostate cancer

Current Cancer Drug Targets

Volumn 11, Issue 7, 2011, Pages 870-881

  Shiota, Masaki ^a   Yokomizo, Akira ^a   Fujimoto, Naohiro ^b   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Androgen; Androgen receptor; Cofactor; Heat shock protein 90; Prostate cancer; Splice variant; Target therapy

Indexed keywords

ANDROGEN RECEPTOR; CYTOSKELETON PROTEIN; GELSOLIN; HEAT SHOCK PROTEIN 60; METHYLTRANSFERASE; PROGESTERONE RECEPTOR; PROTEIN P160; PROTEIN P300; STEROID RECEPTOR COACTIVATOR 1;

CASTRATION; CELL CYCLE REGULATION; CELL PROLIFERATION; DNA REPAIR; HUMAN; HYPERSENSITIVITY; IN VIVO STUDY; MICROARRAY ANALYSIS; PROSTATE CANCER; PROTEIN DOMAIN; REVIEW; RNA PROCESSING; UBIQUITINATION;

CASTRATION; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION FACTORS;

EID: 80051692745     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911796798904     Document Type: Review

References (138)

1. Davison, S. L.; Bell, R. Androgen physiology. Semin. Reprod. Med. 2006, 24, 71-77.
2. Rainey, W. E.; Carr, B. R.; Sasano, H.; Suzuki, T.; Mason, J. I. Dissecting human adrenal androgen production. Trends Endocrinol. Metab. 2002, 13, 234-239.
3. Russell, D. W.; Wilson, J. D. Steroid 5α-reductase: two genes/two enzymes. Annu. Rev. Biochem. 1994, 63, 25-61.
4. Deslypere, J. P.; Young, M.; Wilson, J. D.; McPhaul, M. J. Testosterone and 5α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol. Cell. Endocrinol. 1992, 88, 15-22.
5. Prescott, J.; Coetzee, G. A. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett. 2006, 231, 12-19.
6. Lee, D. K.; Chang, C. Molecular communication between androgen receptor and general transcription machinery. J. Steroid Biochem. Mol. Biol. 2003, 84, 41-49.
7. Heinlein, C. A.; Chang, C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 2002, 23, 175-200.
8. Wang, L.; Hsu, C. L.; Chang, C. Androgen receptor corepressors: an overview. Prostate 2005, 63, 117-130.
9. Tsai, M. J.; O'Malley, B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63, 451-486.
10. White, R.; Parker, M. G. Molecular mechanisms of steroid hormone action. Endocr. Relat. Cancer 1998, 5, 1-14.
11. He, B.; Lee, L. W.; Minges, J. T.; Wilson, E. M. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J. Biol. Chem. 2002, 277, 25631-25639.
12. Jenster, G.; van der Korput, H. A.; Trapman, J.; Brinkmann, A. O. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. 1995, 270, 7341-7346.
13. Giovannucci, E.; Stampfer, M. J.; Krithivas, K.; Brown, M.; Dahl, D.; Brufsky, A.; Talcott, J.; Hennekens, C. H.; Kantoff, P. W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA 1997, 94, 3320-3323.
14. Jenster, G.; Trapman, J.; Brinkmann, A. O. Nuclear import of the human androgen receptor. Biochem. J. 1993, 293, 761-768.
15. Verrijdt, G.; Tanner, T.; Moehren, U.; Callewaert, L.; Haelens, A.; Claessens, F. The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response. Biochem. Soc. Trans. 2006, 34, 1089-1094.
16. Reid, K. J.; Hendy, S. C.; Saito, J.; Sorensen, P.; Nelson, C. C. Two classes of androgen receptor elements mediate cooperativity through allosteric interactions. J. Biol. Chem. 2001, 276, 2943-2952.
17. Zhou, Z. X.; Sar, M.; Simental, J. A.; Lane, M. V.; Wilson, E. M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J. Biol. Chem. 1994, 269, 13115-13123.
18. Heery, D. M.; Kalkhoven, E.; Hoare, S.; Parker, M. G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 387, 733-736.
19. He, B.; Kemppainen, J. A.; Wilson, E. M. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 2000, 275, 22986-22994.
20. Chang, C. Y.; McDonnell, D. P. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol. Endocrinol. 2002, 16, 647-660.
21. Hsu, C. L.; Chen, Y. L.; Yeh, S.; Ting, H. J.; Hu, Y. C.; Lin, H.; Wang, X.; Chang, C. The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. J. Biol. Chem. 2003, 278, 23691-23698.
22. Chang, C. Y.; McDonnell, D. P. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol. Sci. 2005, 26, 225-228.
23. Oñate, S. A.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270, 1354-1357.
24. Heemers, H. V.; Tindall, D. J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 2007, 28, 778-808.
25. Miyamoto, H.; Messing, E. M.; Chang, C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004, 61, 332-353.
26. Roy-Burman, P.; Tindall, D. J.; Robins, D. M.; Greenberg, N. M.; Hendrix, M. J.; Mohla, S.; Getzenberg, R. H.; Isaacs, J. T.; Pienta, K. J. Androgens and prostate cancer: are the descriptors valid? Cancer Biol. Ther. 2005, 4, 4-5.
27. Litvinov, I. V.; De Marzo, A. M.; Isaacs, J. T. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J. Clin. Endocrinol. Metab. 2003, 88, 2972-2982.
28. Debes, J. D.; Tindall, D. J. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 2004, 351, 1488-1490.
29. Titus, M. A.; Schell, M. J.; Lih, F. B.; Tomer, K. B.; Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 2005, 11, 4653-4657.
30. Dehm, S. M.; Schmidt, L. J.; Heemers, H. V.; Vessella, R. L.; Tindall, D. J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68, 5469-5477.
31. Hu, R.; Dunn, T. A.; Wei, S.; Isharwal, S.; Veltri, R. W.; Humphreys, E.; Han, M.; Partin, A. W.; Vessella, R. L.; Isaacs, W. B.; Bova, G. S.; Luo, J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormonerefractory prostate cancer. Cancer Res. 2009, 69, 16-22.
32. Guo, Z.; Yang, X.; Sun, F.; Jiang, R.; Linn, D. E.; Chen, H.; Chen, H.; Kong, X.; Melamed, J.; Tepper, C. G.; Kung, H. J.; Brodie, A. M.; Edwards, J.; Qiu, Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009, 69, 2305-2313.
33. Heemers, H. V.; Tindall, D. J. Androgen receptor coregulatory proteins as potential therapeutic targets in the treatment of prostate cancer. Curr. Cancer Ther. Rev. 2005, 1, 175-186.
34. Heemers, H. V.; Sebo, T. J.; Debes, J. D.; Regan, K. M.; Raclaw, K. A.; Murphy, L. M.; Hobisch, A.; Culig, Z.; Tindall, D. J. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res. 2007, 67, 3422-3430.
35. Heemers, H. V.; Regan, K. M.; Dehm, S. M.; Tindall, D. J. Androgen induction of the androgen receptor co-activator FHL2: evidence for a role for serum response factor in prostate cancer. Cancer Res. 2007, 67, 10592-10599.
36. Anzick, S. L.; Kononen, J.; Walker, R. L.; Azorsa, D. O.; Tanner, M. M.; Guan, X. Y.; Sauter, G.; Kallioniemi, O. P.; Trent, J. M.; Meltzer, P. S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277, 965-968.
37. Chen, H.; Lin, R. J.; Schiltz, R. L.; Chakravarti, D.; Nash, A.; Nagy, L.; Privalsky, M. L.; Nakatani, Y.; Evans, R. M. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997, 90, 569-580.
38. Li, H.; Gomes, P. J.; Chen, J. D. RAC3, a steroid/nuclear receptorassociated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci. USA 1997, 94, 8479-8484.
39. Takeshita, A.; Cardona, G. R.; Koibuchi, N.; Suen, C. S.; Chin, W. W. TRAM-1, A novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J. Biol. Chem. 1997, 272, 27629-27634.
40. Ding, X. F.; Anderson, C. M.; Ma, H.; Hong, H.; Uht, R. M.; Kushner, P. J.; Stallcup, M. R. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol. Endocrinol. 1998, 12, 302-313.
41. Needham, M.; Raines, S.; McPheat, J.; Stacey, C.; Ellston, J.; Hoare, S.; Parker, M. Differential interaction of steroid hormone receptors with LXXLL motifs in SRC-1a depends on residues flanking the motif. J. Steroid Biochem. Mol. Biol. 2000, 72, 35-46.
42. Wang, Q.; Lu, J.; Yong, E. L. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligandbinding domain is inhibited by the cognate hinge region. J. Biol. Chem. 2001, 276, 7493-7499.
43. Spencer, T. E.; Jenster, G.; Burcin, M. M.; Allis, C. D.; Zhou, J.; Mizzen, C. A.; McKenna, N. J.; Onate, S. A.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997, 389, 194-198.
44. Chakravarti, D.; LaMorte, V. J.; Nelson, M. C.; Nakajima, T.; Schulman, I. G.; Juguilon, H.; Montminy, M.; Evans, R. M. Role of CBP/P300 in nuclear receptor signalling. Nature 1996, 383, 99-103.
45. Blanco, J. C.; Minucci, S.; Lu, J.; Yang, X. J.; Walker, K. K.; Chen, H.; Evans, R. M.; Nakatani, Y.; Ozato, K. The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev. 1998, 12, 1638-1651.
46. Lee, D. Y.; Teyssier, C.; Strahl, B. D.; Stallcup, M. R. Role of protein methylation in regulation of transcription. Endocr. Rev. 2005, 26, 147-170.
47. Stallcup, M. R.; Kim, J. H.; Teyssier, C.; Lee, Y. H.; Ma, H.; Chen, D. The roles of protein-protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators. J. Steroid Biochem. Mol. Biol. 2003, 85, 139-145.
48. Korzus, E.; Torchia, J.; Rose, D. W.; Xu, L.; Kurokawa, R.; McInerney, E. M.; Mullen, T. M.; Glass, C. K.; Rosenfeld, M. G. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998, 279, 703-707.
49. Belandia, B.; Parker, M. G. Nuclear receptors: a rendezvous for chromatin remodeling factors. Cell 2003, 114, 277-280.
50. Lewis, B. A.; Reinberg, D. The mediator coactivator complex: functional and physical roles in transcriptional regulation. J. Cell. Sci. 2003, 116, 3667-3675.
51. Gregory, C. W.; He, B.; Johnson, R. T.; Ford, O. H.; Mohler, J. L.; French, F. S.; Wilson, E. M. A mechanism for androgen receptormediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001, 61, 4315-4319.
52. Zhou, H. J.; Yan, J.; Luo, W.; Ayala, G.; Lin, S. H.; Erdem, H.; Ittmann, M.; Tsai, S. Y.; Tsai, M. J. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005, 65, 7976-7983.
53. Gnanapragasam, V. J.; Leung, H. Y.; Pulimood, A. S.; Neal, D. E.; Robson, C. N. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br. J. Cancer 2001, 85, 1928-1936.
54. Debes, J. D.; Sebo, T. J.; Lohse, C. M.; Murphy, L. M.; Haugen de, A. L.; Tindall, D. J. p300 in prostate cancer proliferation and progression. Cancer Res. 2003, 63, 7638-7640.
55. Comuzzi, B.; Nemes, C.; Schmidt, S.; Jasarevic, Z.; Lodde, M.; Pycha, A.; Bartsch, G.; Offner, F.; Culig, Z.; Hobisch, A. The androgen receptor coactivator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J. Pathol. 2004, 204, 159-166.
56. Fu, M.; Wang, C.; Reutens, A. T.; Wang, J.; Angeletti, R. H.; Siconolfi-Baez, L.; Ogryzko, V.; Avantaggiati, M. L.; Pestell, R. G. p300 and p300/cAMPresponse element-binding protein- associated factor acetylate the androgen receptor at sites governing hormonedependent transactivation. J. Biol. Chem. 2000, 275, 20853-20860.
57. Culig, Z.; Steiner, H.; Bartsch, G.; Hobisch, A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr. Relat. Cancer 2005, 12, 229-244.
58. Isharwal, S.; Miller, M. C.; Marlow, C.; Makarov, D. V.; Partin, A. W.; Veltri, R. W. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 2008, 68, 1097-1104.
59. Brady, M. E.; Ozanne, D. M.; Gaughan, L.; Waite, I.; Cook, S.; Neal, D. E.; Robson, C. N. Tip60 is a nuclear hormone receptor coactivator. J. Biol. Chem. 1999, 274, 17599-17604.
60. Halkidou, K.; Gnanapragasam, V. J.; Mehta, P. B.; Logan, I. R.; Brady, M. E.; Cook, S.; Leung, H. Y.; Neal, D. E.; Robson, C. N. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003, 22, 2466-2477.
61. Shiota, M.; Yokomizo, A.; Masubuchi, D.; Tada, Y.; Inokuchi, J.; Eto, M.; Uchiumi, T.; Fujimoto, N.; Naito, S. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate 2010, 70, 540-554.
62. Kim, J. H.; Kim, B.; Cai, L.; Choi, H. J.; Ohgi, K. A.; Tran, C.; Chen, C.; Chung, C. H.; Huber, O.; Rose, D. W.; Sawyers, C. L.; Rosenfeld, M. G.; Baek, S. H. Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes. Nature 2005, 434, 921-926.
63. Majumder, S.; Liu, Y.; Ford, O. H. 3rd.; Mohler, J. L.; Whang, Y. E. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate 2006, 66, 1292-1301.
64. Hong, H.; Kao, C.; Jeng, M. H.; Eble, J. N.; Koch, M. O.; Gardner, T. A.; Zhang, S.; Li, L.; Pan, C. X.; Hu, Z.; MacLennan, G. T.; Cheng, L. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 2004, 101, 83-89.
65. Lee, D. Y.; Northrop, J. P.; Kuo, M. H.; Stallcup, M. R. Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors. J. Biol. Chem. 2006, 281, 8476-8485.
66. Shiota, M.; Song, Y.; Yokomizo, A.; Tada, Y.; Kuroiwa, K.; Eto, M.; Oda, Y.; Inokuchi, J.; Uchiumi, T.; Fujimoto, N.; Seki, N.; Naito, S. Human heterochromatin protein 1 isoform HP1β enhances androgen receptor activity and is implicated in prostate cancer growth. Endocr. Relat. Cancer 2010, 17, 455-467.
67. Miyajima, N.; Maruyama, S.; Bohgaki, M.; Kano, S.; Shigemura, M.; Shinohara, N.; Nonomura, K.; Hatakeyama, S. TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. Cancer Res. 2008, 68, 3486-3494.
68. Xu, K.; Shimelis, H.; Linn, D. E.; Jiang, R.; Yang, X.; Sun, F.; Guo, Z.; Chen, H.; Li, W.; Chen, H.; Kong, X.; Melamed, J.; Fang, S.; Xiao, Z.; Veenstra, T. D.; Qiu, Y. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 2009, 15, 270-282.
69. Clark, E. L.; Coulson, A.; Dalgliesh, C.; Rajan, P.; Nicol, S. M.; Fleming, S.; Heer, R.; Gaughan, L.; Leung, H. Y.; Elliott, D. J.; Fuller-Pace, F. V.; Robson, C. N. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res. 2008, 68, 7938-7946.
70. Rajan, P.; Gaughan, L.; Dalgliesh, C.; El-Sherif, A.; Robson, C. N.; Leung, H. Y.; Elliott, D. J. The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J. Pathol. 2008, 215, 67-77.
71. Kwiatkowski, D. J. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr. Opin. Cell. Biol. 1999, 11, 103-108.
72. Nishimura, K.; Ting, H. J.; Harada, Y.; Tokizane, T.; Nonomura, N.; Kang, H. Y.; Chang, H. C.; Yeh, S.; Miyamoto, H.; Shin, M.; Aozasa, K.; Okuyama, A.; Chang, C. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res. 2003, 63, 4888-4894.
73. Lee, H. K.; Driscoll, D.; Asch, H.; Asch, B.; Zhang, P. J. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999, 40, 14-19.
74. Asch, H. L.; Head, K.; Dong, Y.; Natoli, F.; Winston, J. S.; Connolly, J. L.; Asch, B. B. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res. 1996, 56, 4841-4845.
75. Dosaka-Akita, H.; Hommura, F.; Fujita, H.; Kinoshita, I.; Nishi, M.; Morikawa, T.; Katoh, H.; Kawakami, Y.; Kuzumaki, N. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res. 1998, 58, 322-327.
76. Tanaka, M.; Mullauer, L.; Ogiso, Y.; Fujita, H.; Moriya, S.; Furuuchi, K.; Harabayashi, T.; Shinohara, N.; Koyanagi, T.; Kuzumaki, N. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res. 1995, 55, 3228-3232.
77. Pope, R. K.; Pestonjamasp, K. N.; Smith, K. P.; Wulfkuhle, J. D.; Strassel, C. P.; Lawrence, J. B.; Luna, E. J. Cloning, characterization, and chromosomal localization of human superillin (SVIL). Genomics 1998, 52, 342-351.
78. Ting, H. J.; Yeh, S.; Nishimura, K.; Chang, C. Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 661-666.
79. Pestonjamasp, K. N.; Pope, R. K.; Wulfkuhle, J. D.; Luna, E. J. Supervillin (p205): A novel membrane-associated, F-actin-binding protein in the villin/gelsolin superfamily. J. Cell. Biol. 1997, 139, 1255-1269.
80. Gorlin, J. B.; Yamin, R.; Egan, S.; Stewart, M.; Stossel, T. P.; Kwiatkowski, D. J.; Hartwig, J. H. Human endothelial actinbinding protein (ABP-280, nonmuscle filamin): a molecular leaf spring. J. Cell. Biol. 1990, 111, 1089-1105.
81. Loy, C. J.; Sim, K. S.; Yong, E. L. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 4562-4567.
82. Wang, Y.; Kreisberg, J. I.; Bedolla, R. G.; Mikhailova, M.; de Vere White, R. W.; Ghosh, P. M. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene 2007, 26, 6061-6070.
83. Bedolla, R. G.; Wang, Y.; Asuncion, A.; Chamie, K.; Siddiqui, S.; Mudryj, M. M.; Prihoda, T. J.; Siddiqui, J.; Chinnaiyan, A. M.; Mehra, R.; de Vere White, R. W.; Ghosh, P. M. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin. Cancer Res. 2009, 15, 788-796.
84. Zheng, P.; Eastman, J.; Vande Pol, S.; Pimplikar, S. W. PAT1, a microtubule-interacting protein, recognizes the basolateral sorting signal of amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 14745-14750.
85. Zhang, Y.; Yang, Y.; Yeh, S.; Chang, C. ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol. Cell. Biol. 2004, 24, 1044-1057.
86. Burd, C. J.; Petre, C. E.; Moghadam, H.; Wilson, E. M.; Knudsen, K. E. Cyclin D1 binding to the androgen receptor (AR) NH2- terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol. Endocrinol. 2005, 19, 607-620.
87. Reutens, A. T.; Fu, M.; Wang, C.; Albanese, C.; McPhaul, M. J.; Sun, Z.; Balk, S. P.; Jänne, O. A.; Palvimo, J. J.; Pestell, R. G. Cyclin D1 binds the androgen receptor and regulates hormonedependent signaling in a p300/CBP-associated factor (P/CAF)- dependent manner. Mol. Endocrinol. 2001, 15, 797-811.
88. Petre-Draviam, C. E.; Williams, E. B.; Burd, C. J.; Gladden, A.; Moghadam, H.; Meller, J.; Diehl, J. A.; Knudsen, K. E. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 2005, 24, 431-444.
89. Comstock, C. E.; Revelo, M. P.; Buncher, C. R.; Knudsen, K. E. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br. J. Cancer 2007, 96, 970-979.
90. Burd, C. J.; Petre, C. E.; Morey, L. M.; Wang, Y.; Revelo, M. P.; Haiman, C. A.; Lu, S.; Fenoglio-Preiser, C. M.; Li, J.; Knudsen, E. S.; Wong, J.; Knudsen, K. E. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 2190-2195.
91. Comstock, C. E.; Augello, M. A.; Benito, R. P.; Karch, J.; Tran, T. H.; Utama, F. E.; Tindall, E. A.; Wang, Y.; Burd, C. J.; Groh, E. M.; Hoang, H. N.; Giles, G. G.; Severi, G.; Hayes, V. M.; Henderson, B. E.; Le Marchand, L.; Kolonel, L. N.; Haiman, C. A.; Baffa, R.; Gomella, L. G.; Knudsen, E. S.; Rui, H.; Henshall, S. M.; Sutherland, R. L.; Knudsen, K. E. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin. Cancer Res. 2009, 15, 5338-5349.
92. Schiewer, M. J.; Morey, L. M.; Burd, C. J.; Liu, Y.; Merry, D. E.; Ho, S. M.; Knudsen, K. E. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene 2009, 28, 1016-1027.
93. Ngan, E. S.; Hashimoto, Y.; Ma, Z. Q.; Tsai, M. J.; Tsai, S. Y. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003, 22, 734-739.
94. Nagata, A.; Igarashi, M.; Jinno, S.; Suto, K.; Okayama, H. An additional homolog of the fission yeast cdc251 gene occurs in humans and is highly expressed in some cancer cells. New Biol. 1991, 3, 959-968.
95. Hernandez, S.; Bessa, X.; Bea, S.; Hernandez, L.; Nadal, A.; Mallofre, C.; Muntane, J.; Castells, A.; Fernandez, P. L.; Cardesa, A.; Campo, E. Differential expression of cdc25 cell-cycleactivating phosphatases in human colorectal carcinoma. Lab. Invest. 2001, 81, 465-473.
96. Gasparotto, D.; Maestro, R.; Piccinin, S.; Vukosavljevic, T.; Barzan, L.; Sulfaro, S.; Boiocchi, M. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 1997, 57, 2366-2368.
97. Galaktionov, K.; Lee, A. K.; Eckstein, J.; Draetta, G.; Meckler, J.; Loda, M.; Beach, D. CDC25 phosphatases as potential human oncogenes. Science 1995, 269, 1575-1577.
98. Ray, M. R.; Wafa, L. A.; Cheng, H.; Snoek, R.; Fazli, L.; Gleave, M.; Rennie, P. S. Cyclin G-associated kinase: a novel androgen receptorinteracting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int. J. Cancer 2006, 118, 1108-1119.
99. Taneja, S. S.; Ha, S.; Swenson, N. K.; Torra, I. P.; Rome, S.; Walden, P. D.; Huang, H. Y.; Shapiro, E.; Garabedian, M. J.; Logan, S. K. ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J. Biol. Chem. 2004, 279, 13944-13952.
100. Hu, Y. C.; Yeh, S.; Yeh, S. D.; Sampson, E. R.; Huang, J.; Li, P.; Hsu, C. L.; Ting, H. J.; Lin, H. K.; Wang, L.; Kim, E.; Ni, J.; Chang, C. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J. Biol. Chem. 2004, 279, 33438-33446.
101. Li, P.; Yu, X.; Ge, K.; Melamed, J.; Roeder, R. G.; Wang, Z. Heterogeneous expression and functions of androgen receptor cofactors in primary prostate cancer. Am. J. Pathol. 2002, 161, 467-1474.
102. Chang, H. C.; Chen, S. C.; Chen, J.; Hsieh, J. T. In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line. J. Formos. Med. Assoc. 2005, 104, 652-658.
103. Mestayer, C.; Blanchere, M.; Jaubert, F.; Dufour, B.; Mowszowicz, I. Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate 2003, 56, 192-200.
104. Shiota, M.; Yokomizo, A.; Tada, Y.; Inokuchi, J.; Tatsugami, K.; Kuroiwa, K.; Uchiumi, T.; Fujimoto, N.; Seki, N.; Naito, S. Peroxisome proliferator-activated receptor Υ coactivator-1α interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol. Endocrinol. 2010, 24, 114-127.
105. Hsiao, P. W.; Lin, D. L.; Nakao, R.; Chang, C. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J. Biol. Chem. 1999, 274, 20229-20234.
106. Linja, M. J.; Porkka, K. P.; Kang, Z.; Savinainen, K. J.; Janne, O. A.; Tammela, T. L.; Vessella, R. L.; Palvimo, J. J.; Visakorpi, T. Expression of androgen receptor coregulators in prostate cancer. Clin. Cancer Res. 2004, 10, 1032-1040.
107. Fujimoto, N.; Yeh, S.; Kang, H. Y.; Inui, S.; Chang, H. C.; Mizokami, A.; Chang, C. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J. Biol. Chem. 1999, 274, 8316-8321.
108. Kasai, M.; Guerrero-Santoro, J.; Friedman, R.; Leman, E. S.; Getzenberg, R. H.; DeFranco, D. B. The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Res. 2003, 63, 4927-4935.
109. Miyoshi, Y.; Ishiguro, H.; Uemura, H.; Fujinami, K.; Miyamoto, H.; Kitamura, H.; Kubota, Y. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003, 56, 280-286.
110. Yoon, H. G.; Wong, J. The corepressors SMRT and N-CoR are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol. Endocrinol. 2006, 20, 1048-1060.
111. Berrevoets, C. A.; Umar, A.; Trapman, J.; Brinkmann, A. O. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR). Biochem. J. 2004, 379, 731-738.
112. Shang, Y.; Myers, M.; Brown, M. Formation of the androgen receptor transcription complex. Mol. Cell 2002, 9, 601-610.
113. Dotzlaw, H.; Moehren, U.; Mink, S.; Cato, A. C.; Iniguez Lluhi, J. A.; Baniahmad, A. The amino terminus of the human AR is target for corepressors action and antihormone agonism. Mol. Endocrinol. 2002, 16, 661-673.
114. Jackson, T. A.; Richer, J. K.; Bain, D. L.; Takimoto, G. S.; Tung, L.; Horwitz, K. B. The partial agonist activity of antagonistoccupied steroid receptors is controlled by a novel hinge domainbinding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 1997, 11, 693-705.
115. Liao, G.; Chen, L. Y.; Zhang, A.; Godavarthy, A.; Xia, F.; Ghosh, J. C.; Li, H.; Chen, J. D. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J. Biol. Chem. 2003, 278, 5052-5061.
116. Miyamoto, H.; Rahman, M. M.; Chang, C. Molecular basis for the antiandrogen withdrawal syndrome. J. Cell. Biochem. 2004, 91, 3-12.
117. Nessler-Menardi, C.; Jotova, I.; Culig, Z.; Eder, I. E.; Putz, T.; Bartsch, G.; Klocker, H. Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate 2000, 45, 124-131.
118. Fujimoto, N.; Mizokami, A.; Harada, S.; Matsumoto, T. Different expression of androgen receptor coactivators in human prostate. Urology 2001, 58, 289-294.
119. Lapointe, J.; Li, C.; Higgins, J. P.; van de Rijn, M.; Bair, E.; Montgomery, K.; Ferrari, M.; Egevad, L.; Rayford, W.; Bergerheim, U.; Ekman, P.; DeMarzo, A. M.; Tibshirani, R.; Botstein, D.; Brown, P. O.; Brooks, J. D.; Pollack, J. R. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. USA 2004, 101, 811-816.
120. Dhanasekaran, S. M.; Barrette, T. R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K. J.; Rubin, M. A.; Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412, 822-826.
121. Magee, J. A.; Araki, T.; Patil, S.; Ehrig, T.; True, L.; Humphrey, P. A.; Catalona, W. J.; Watson, M. A.; Milbrandt, J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001, 61, 5692-5696.
122. LaTulippe, E.; Satagopan, J.; Smith, A.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W. L. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002, 62, 4499-4506.
123. Singh, D.; Febbo, P. G.; Ross, K.; Jackson, D. G.; Manola, J.; Ladd, C.; Tamayo, P.; Renshaw, A. A.; D'Amico, A. V.; Richie, J. P.; Lander, E. S.; Loda, M.; Kantoff, P. W.; Golub, T. R.; Sellers, W. R. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1, 203-209.
124. Luo, J. H.; Yu, Y. P.; Cieply, K.; Lin, F.; Deflavia, P.; Dhir, R.; Finkelstein, S.; Michalopoulos, G.; Becich, M. Gene expression analysis of prostate cancers. Mol. Carcinog. 2002, 33, 25-35.
125. Yu, Y. P.; Landsittel, D.; Jing, L.; Nelson, J.; Ren, B.; Liu, L.; McDonald, C.; Thomas, R.; Dhir, R.; Finkelstein, S.; Michalopoulos, G.; Becich, M.; Luo, J. H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 2004, 22, 2790-2799.
126. Welsh, J. B.; Sapinoso, L. M.; Su, A. I.; Kern, S. G.; Wang-Rodriguez, J.; Moskaluk, C. A.; Frierson, H. F. Jr.; Hampton, G. M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001, 61, 5974-5978.
127. Chmelar, R.; Buchanan, G.; Need, E. F.; Tilley, W.; Greenberg, N. M. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer 2007, 120, 719-733.
128. Rahman, M. M.; Miyamoto, H.; Takatera, H.; Yeh, S.; Altuwaijri, S.; Chang, C. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J. Biol. Chem. 2003, 278, 19619-19626.
129. Rahman, M. M.; Miyamoto, H.; Lardy, H.; Chang, C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 5124-5129.
130. Miyamoto, H.; Rahman, M.; Takatera, H.; Kang, H. Y.; Yeh, S.; Chang, H. C.; Nishimura, K.; Fujimoto, N.; Chang, C. A dominantnegative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J. Biol. Chem. 2002, 277, 4609-4617.
131. Heemers, H. V.; Regan, K. M.; Schmidt, L. J.; Anderson, S. K.; Ballman, K. V.; Tindall, D. J. Androgen modulation of coregulator expression in prostate cancer cells. Mol. Endocrinol. 2009, 23, 572-583.
132. Heemers, H. V, Schmidt, L. J.; Kidd, E.; Raclaw, K. A.; Regan, K. M.; Tindall, D. J. Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells. Prostate 2010, 70, 959-970.
133. Schnur, R. C.; Corman, M. L.; Gallaschun, R. J.; Cooper, B. A.; Dee, M. F.; Doty, J. L.; Muzzi, M. L.; Moyer, J. D.; DiOrio, C. I.; Barbacci, E. G.; Miller, P. E.; O'Brien, A. T.; Morin, M. J.; Foster, B. A.; Pollack, V. A.; Savage, D. M.; Sloan, D. E.; Pustilnik, L. R.; Moyer, M. P. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 1995, 38, 3806-3812.
134. Solit, D. B.; Zheng, F. F.; Drobnjak, M.; Münster, P. N.; Higgins, B.; Verbel, D.; Heller, G.; Tong, W.; Cordon-Cardo, C.; Agus, D. B.; Scher, H. I.; Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 2002, 8, 986-993.
135. Heath, E. I.; Hillman, D. W.; Vaishampayan, U.; Sheng, S.; Sarkar, F.; Harper, F.; Gaskins, M.; Pitot, H. C.; Tan, W.; Ivy, S. P.; Pili, R.; Carducci, M. A.; Erlichman, C.; Liu, G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormonerefractory metastatic prostate cancer. Clin. Cancer Res. 2008, 14, 7940-7946.
136. Marivoet, S.; Van Dijck, P.; Verhoeven, G.; Heyns, W. Interaction of the 90-kDa heat shock protein with native and in vitro translated androgen receptor and receptor fragments. Mol. Cell. Endocrinol. 1992, 88, 165-174.
137. Andersen, R. J.; Mawji, N. R.; Wang, J.; Wang, G.; Haile, S.; Myung, J. K.; Watt, K.; Tam, T.; Yang, Y. C.; Bañuelos, C. A.; Williams, D. E.; McEwan, I. J.; Wang, Y.; Sadar, M. D. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010, 17, 535-546.
138. van de Wijngaart, D. J.; Dubbink, H. J.; Molier, M.; de Vos, C.; Jenster, G.; Trapman, J. Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cellpenetrating peptides, and lentiviral infection. Prostate 2011, 71, 241-253.